AstraZeneca PLC (AZN)vsSophia Genetics SA (SOPH)
AZN
AstraZeneca PLC
$173.30
-1.13%
HEALTHCARE · Cap: $261.94B
SOPH
Sophia Genetics SA
$5.76
+3.78%
HEALTHCARE · Cap: $492.46M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 74351% more annual revenue ($60.44B vs $81.18M). AZN leads profitability with a 17.2% profit margin vs -99.7%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SOPH
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$193.96
Current Price
$173.30
$20.66 discount
Intrinsic value data unavailable for SOPH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.9%
Generating 2.1B in free cash flow
Revenue surging 22.0% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Trading at 9.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SOPH
The strongest argument for SOPH centers on Revenue Growth. Revenue growth of 22.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SOPH
The primary concerns for SOPH are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while SOPH is a growth play — different risk/reward profiles.
SOPH carries more volatility with a beta of 0.96 — expect wider price swings.
SOPH is growing revenue faster at 22.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 26/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sophia Genetics SA
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Sophia Genetics SA (SOPH) stands at the forefront of data-driven medicine, delivering advanced genomic and clinical data analytics that significantly enhance patient outcomes. Utilizing cutting-edge machine learning technologies, the company provides an integrated platform designed to help healthcare providers navigate complex genomic data, facilitating personalized treatment strategies in oncology, rare diseases, and hereditary conditions. With a robust global footprint and strategic partnerships with leading healthcare organizations, Sophia Genetics is well-positioned to transform the precision medicine landscape and solidify its role as a key player in the genomics industry.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?